914.385.0200
info@bioscienceresearchllc.com | Home
359 East Main Street, Suite 3I, Mount Kisco, NY, 10549
914.385.0200
info@bioscienceresearchllc.com | Home
359 East Main Street, Suite 3I, Mount Kisco, NY, 10549

Past Clinical Trials

    1. A Multi-center, 10-Week, Randomized, Double-blind Study of Sertraline and Placebo in Children and Adolescents with Post-traumatic Stress Disorder. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Pfizer Pharmaceuticals Group; January 2003.

    2. A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults with Attention-Defecit/Hyperactivity Disorder: with a Secondary Examination of Impact of Treatment on Family Functioning. Principal Investigator: David Sert Krakow, M.D., Co-Investigator: Jeanette E. Cueva, M.D.; Sponsor: Eli Lilly & Company; 2004.

    3. A Multi-center, Open-label Safety and Tolerability Study of Flexible-Dose Oral Aripiprazole (2mg – 30mg) in the Treatment of Adolescent Patients with Schizophrenia, and Child and Adolescent Patients with Bipolar I Disorder, Manic or Mixed Episode. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Otsuka Maryland Research Institute, Inc., February 2005.

    4. A Multi-center, Randomized, Double-blind, Placebo-controlled Study with Two Fixed Oral Doses of Aripiprazole (10mg or 30mg) in the Treatment of Adolescent Patients with Schizophrenia. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Otsuka Maryland Research Institute, Inc., 2005.

    5. A Multi-center, Randomized, Double-blind, Placebo-controlled Study of Two Fixed Oral Doses of Aripiprazole (10mg or 30mg) in the Treatment of Child and Adolescent Patients Aged 10–17 Years, with Bipolar I Disorder, Manic or Mixed Episode with or without Psychotic Features. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Otsuka Maryland Research Institute, Inc., February 2005.

    6. A Randomized, Multicenter, Double-Blind, Parallel Group Study to Compare the Effects of Bifeprunox and Quetiapine on Weight Changes in Stable Schizophrenia Patients. Principal Investigator: David Sert Krakow, M.D., Co-Investigator: Jeanette E. Cueva, M.D.; Sponsor: Solvay Pharmaceuticals; January 2007.

    7. A Multicenter, Randomized, Double-Blind, Placebo and Escitalopram Controlled Trial of the Safety and Efficacy of BMS-562086 in the Treatment of Outpatients with Major Depressive Disorder. Principal Investigator: David Sert Krakow, M.D., Co-Investigator: Jeanette E. Cueva, M.D.; Sponsor: Bristol-Myers Squibb Pharmaceutical Research Institute; March 2007.

    8. A Multicenter, Randomized, Double-Blind, Placebo and Escitalopram Controlled Trial of the Safety and Efficacy of Pexacerfont (BMS-562086) in the Treatment of Outpatients with Generalized Anxiety Disorder. Principal Investigator: David Sert Krakow, M.D., Co-Investigator: Jeanette E. Cueva, M.D.; Sponsor: Bristol-Myers Squibb Pharmaceutical Research Institute; July 2007.

    9. An Open-Label Study of Tolerability, Safety, and Pharmacokinetics of Duloxetine in the Treatment of Children and Adolescents with Major Depressive Disorder. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Eli Lilly and Company; August 2007.

    10. A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients with Major Depression Disorder. Principal Investigator: David Krakow, M.D., Co-Investigator: Jeanette Cueva, M.D.; Sponsor: PGx Health; January 2008.

    11. A Phase III, Open-label Study of SPD503 in Children and Adolescents aged 6–17 with Attention Deficit Hyperactivity Disorder. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Shire Pharmaceutical Development, Inc., February 2008.

    12. A Phase III, Randomized, Multi-center, Double-blind, Parallel-group, Placebo-controlled Safety and Efficacy Study of SPD503 in Children and Adolescents aged 6–17 with Attention Deficit Hyperactivity Disorder. Principal Investigator: Jeanette E. Cueva, M.D., Co-Investigator: David Sert Krakow, M.D.; Sponsor: Shire Pharmaceutical Development, Inc., February 2008.

    13. A 12 Week, Randomized, Open-Label Trial of Duloxetine Versus Generic SSRIs in the Treatment of a Severe Depressive Episode. Principal Investigator: David Krakow, M.D., Co-Investigator: Jeanette Cueva, M.D.; Sponsor: Eli Lilly, May 2008.

    14. The Evaluation of LAMICTAL™ as an Add-on Treatment for Bipolar I Disorder in Children and Adolescents, 10 to 17 Years of Age. Principal Investigator: Jeanette Cueva, M.D., Co-Investigator: David Krakow, M.D.; Sponsor: GlazoSmithKline, July 2008.

    15. A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multi-center, Dose Optimization Study Evaluating the Efficacy and Safety of SPD503 in Combination With Psychostimulants in Children and Adolescents Aged 6-17 With a Diagnosis of ADHD. Principal Investigator: Jeanette Cueva, M.D., Co-Investigator: David Krakow, M.D.; Sponsor: Shire Pharmaceutical Development, Inc., September 2008.

    16. A Phase III, Open-Label, Extension, Multi-center, Safety and Efficacy Study of LDX in Adolescents Aged 13-17 with ADHD. Principal Investigator: Jeanette Cueva, M.D., Co-Investigator: David Krakow, M.D.; Sponsor: Shire Pharmaceutical Development, Inc., October 2008.

    17. A Phase III, Randomized, Double-Blind, Multi-center, Parallel-Group, Placebo-Controlled, Forced-Dose Titration, Safety and Efficacy Study of LDX in Adolescents Aged 13-17 With ADHD. Principal Investigator: Jeanette Cueva, M.D., Co-Investigator: David Krakow, M.D.; Sponsor: Shire Pharmaceutical Development, Inc., October 2008.

    18. A Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Efficacy and Safety Study of AZDXXXX in the Treatment of Generalized Anxiety Disorder (GAD). Principal Investigator: David Krakow, M.D., Co-Investigator: Jeanette Cueva, M.D.; Sponsor: AstraZeneca, February 2009.

    19. A Multicenter, Long-Term, Open-Label Study to Assess the Safety and Tolerability of OPC-XXX as Adjunctive Therapy in the Treatment of Outpatients with Major Depressive Disorder. Principal Investigator: David Krakow, M.D., Co-Investigator: Jeanette Cueva, M.D.; Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc., May 2009.

    20. A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of OPC-XXX as Adjunctive Therapy in the Treatment of Patients with Major Depressive Disorder. Principal Investigator: David Krakow, M.D., Co-Investigator: Jeanette Cueva, M.D.; Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc., May 2009.

    21. A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, Multicenter Study of 3 Dosages of JNJ-XXX in the Treatment of Adult Subjects with Attention-Deficit/Hyperactivity Disorder. Principal Investigator: David Krakow, M.D., Co-Investigator: Jeanette Cueva, M.D.; Sponsor: Johnson & Johnson Pharmaceutical Development & Commercialization, Inc., May 2009.

    22. A Double-blind, placebo-controlled study of Cariprazine as adjunctive therapy in Major Depressive Disorder. Principal Investigator: David Krakow, M.D., Co-Investigator: Jeanette Cueva, M.D.; Sponsor: Forest Laboratories, July 2009.

    23. A Study to Assess the Long-Term Efficacy and Safety of Olanzapine and Fluoxetine Combination Versus Fluoxetine Only in the Relapse Prevention of Stabilized Patients with Treatment-Resistant Depression. Principal Investigator: David Krakow, M.D., Co-Investigator: Jeanette Cueva, M.D.; Sponsor: Eli Lilly, August 2009.

    24. A 12 week, randomized, double-blind, placebo-controlled, phase III safety trial of XXX tablets (100 milligrams daily) in women taking a selective serotonin or serotonin –norepinephrine reuptake inhibitor with decreased sexual desire and distress. Principal Investigator: David Krakow, M.D., Co-Investigator: Jeanette Cueva, M.D.; Sponsor: Boehringer-Ingelheim Pharmaceuticals, March 2010.

    25. A Phase 4, randomized, double-blind, multicenter, placebo-controlled, parallel group study evaluating the safety and efficacy of XXX on executive function (self-regulation) behaviors in adults with ADHD reporting clinically significant impairment of real-world executive function behavior. Principal Investigator: David Krakow, M.D., Co-Investigator: Jeanette Cueva, M.D.; Sponsor: Shire Pharmaceutical Development, Inc., April 2010.

We encourage you to contact us if you have any questions or would like more information about our services.

If you are interested in volunteering to participate in a clinical trial:

Apply Online: Click Here
Email: info@bioscienceresearchllc.com
Phone: 914.385.0200

If you are a sponsor or CRO please feel free to call or email us with any questions you may have:

Email: info@bioscienceresearchllc.com
Phone: 914.385.0200

For directions to the office, please visit Location and Directions.